Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection

Blood

Volumn 111, Issue 10, 2008, Pages 5101-5108

  Ghia, Emanuela M ^a,b   Jain, Sonia ^a,b   Ii II, George F Widhopf ^a,b   Rassenti, Laura Z ^a,b   Keating, Michael J ^a,c   Wierda, William G ^a,c   Gribben, John G ^a,d   Brown, Jennifer R ^a,e   Rai, Kanti R ^a,f   Byrd, John C ^a,g   Kay, Neil E ^a,h   Greaves, Andrew W ^a,b   Kipps, Thomas J ^a,b,i  

^a Chronic Lymphocytic Leukemia Research Consortium   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN MOTIF; RISK FACTOR; SOMATIC MUTATION; B CELL LEUKEMIA; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; EPIDEMIOLOGY; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; PROGNOSIS;

AMINO ACID SEQUENCE; B-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; EPIDEMIOLOGY, MOLECULAR; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS;

EID: 46749099871     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-130229     Document Type: Article

References (56)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
2. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor tor VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2001;97:1892-1894.
3. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
5. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk adapted therapeutic strategies. Haematologica. 2005;90:391-399.
6. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003;21:3928-3932.
7. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
8. Matrai Z, Lin K, Dennis M, et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood. 2001:97:1902-1903.
9. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001 ;115:854-861.
10. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404-1409.
11. Krober A, SeilerT, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
12. Tobin G, Thunberg U. Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262-2264.
13. Tobin G. The immunoglobulin genes and chronic lymphocytic leukaemia (GLL). Uppsala J Med Sci. 2004:109:97-114.
14. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952-4957.
15. Falt S, Merup M, Tobin G, et al. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood. 2005;106:681-689.
16. Nollet F, Cauwelier B, Billiet J, et al. Do B-cell chronic lymphocytic leukemia patients with Ig VH3-21 genes constitute a new subset of chronic lymphocytic leukemia? Blood. 2002;100:1097-1098. 2002; author reply 1098-1099.
17. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105:1678-1685.
18. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21 -using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107:2889-2894.
19. Widhopf GF2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1 % of patients express virtually identical immunoglobulins. Blood. 2004;104:2499-2504.
20. Rassenti LZ, KohsakaH, Kipps TJ. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995;764:463-473.
21. Rassenti LZ, Kipps TJ. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med. 1997;185:1435-1445.
22. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
23. Lefranc MP, Giudicelli V, Kaas Q, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2005;33:D593-D597.
24. Giudicelli V, Chaume D, Lefranc MP. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res. 2004;32:W435-W440.
25. Ghia P, Stamatopoulos K, Belessi C, et al. ERIC
26. recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21:1-3.
27. Webster's New World Medical Dictionary ed 2. New York: Wiley; 2003.
28. Corbett SJ, Tomlinson IM, Sonnhammer EL, Buck D, Winter G. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DlR segments, inverted D segments, '"minor" D segments or D-D recombination. J Mol Biol. 1997;270:587-597.
29. Kabat E, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest, ed 5. Bethesda, MD: U.S. Department of Health and Human Services; 1991.
30. van der Burg M, TumkayaT, Boerma M, de BruinVersteeg S, Langerak AW, van Dongen JJ. Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at the IGL locus. Blood. 2001 ;97:1001-1008.
31. Belessi C, Stamatopoulos K, Hadzidimitriou A, et al. Analysis of expressed and non-expressed IGK locus rearrangements in chronic lymphocytic leukemia. Mol Med. 2005;11:52-58.
32. Lossos IS, Tibshirani R, Narasimhan B, Levy R. The inference of antigen selection on Ig genes. J Immunol. 2000;165:5122-5126.
33. Belessi CJ, Davi FB, Stamatopoulos KE, et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. Eur J Immunol. 2006;36:1963-1974.
34. Stamatopoulos K, Belessi C, Moreno C, et al.Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007:109:259-270.
35. Bomben R, Dal Bo M, Capello D, et al. Comprehensive characterization of IGHV3-21-expressing
36. B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood. 2007;109:2989-2998.
37. Widhopt GF2nd, Goldberg CJ,Toy TL, et al. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 2008;111:3137-3144.
38. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science. 2002;297:2066-2070.
39. Toellner KM, Jenkinson WE, Taylor DR, et al. Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers. J Exp Med. 2002:195:383-389.
40. Weller S, Faili A, Garcia C, etal. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA. 2001 ;98:1166-1170.
41. Rassenti LZ, Pratt LF Chen PP, Carson DA, Kipps TJ. Autoantibody-encoding kappa L chain genes frequently rearranged in lambda L chain-expressing chronic lymphocytic leukemia. J Immunol. 1991;147:1060-1066.
42. Nemazee D. Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol. 2006;6:728-740.
43. Verkoczy LK, Martensson AS, Nemazee D. The scope of receptor editing and its association with autoimmunity. Curr Opin Immunol. 2004;16:808-814.
44. Li H, Jiang Y, Prak EL, Radic M, Weigert M. Editors and editing of anti-DNA receptors. Immunity. 2001;15:947-957.
45. Li Y, Li H, Ni D, Weigert M. Anti-DNA B cells in MRL/lpr mice show altered differentiation and editing pattern. J Exp Med. 2002;196:1543-1552.
46. Li Y, Li H, Weigert M. Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med. 2002;195:181-188.
47. Li H, Jiang Y, Cao H, Radic M, Prak EL, Weigert M. Regulation of anti-phosphatidylserine antibodies. Immunity. 2003;18:185-192.
48. Buhl AM, Nemazee D, Cambier JC, Rickert R, Hertz M. B-cell antigen receptor competence regulates B-lymphocyte selection and survival. Immunol Rev. 2000;176:141-153.
49. Kraus M, Saijo K, Torres RM, Rajewsky K. Ig-alpha cytoplasmic truncation renders immature B cells more sensitive to antigen contact. Immunity. 1999;11:537-545.
50. Torres RM, Hafen K. A negative regulatory role for Ig-alpha during B cell development. Immunity. 1999;11:527-536.
51. Hertz M, Nemazee D. Receptor editing and commitment in B lymphocytes. Curr Opin Immunol. 1998;10:208-213.
52. DornerT, Foster SJ, Farner NL, Lipsky PE. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J Clin Invest. 1998;102:688-694.
53. Itoh K, Meffre E, Albesiano E, et al. Immunoglobulin heavy chain variable region gene replacement as a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes. J Exp Med. 2000;192:1151-1164.
54. Sening W, Lisner R, Niedobitek G. Rare detection of phenotypically immature lymphocytes in Hashimoto thyroiditis and rheumatoid arthritis. J Auto-immun. 2004;22:147-152.
55. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol. 2003;171:2725-2733.
56. Lenze D, Greiner A, Knorr C, Anagnostopoulos I, Stein H, Hummel M. Receptor revision of immunoglobulin heavy chain genes in human MALT lymphomas. Mol Pathol. 2003;56:249-255.